Table 1 Patient characteristics of the ST-ICI cohort
| Patient characteristics |
All patients n = 104 (%) |
|---|---|
| Sex | |
| Male | 76 (73) |
| Female | 28 (27) |
| Median age ± SD (years) | 66 ± 10.2 |
| Treatment arm | |
| IT-RT | 50 (48) |
| IT-only | 54 (52) |
| Location of radiotherapya (n = 50) | |
| Lung | 17 (34) |
| CNS | 10 (20) |
| Bone | 5 (10) |
| Other | 18 (36) |
| PD-L1 tumor cells | |
| < 1% | 36 (35) |
| 1–49% | 33 (32) |
| ≥ 50% | 32 (31) |
| Unknown | 3 (3) |
| Brain metastases | 24 (23) |
| Tumor entity | |
| NSCLC | 46 (44) |
| HNSCC | 44 (42) |
| Bladder cancer | 5 (5) |
| Oesophageal cancer | 4 (4) |
| Other | 5 (5) |
| Number of previous treatments | |
| 0–1 | 61 (59) |
| ≥ 2 | 43 (41) |
| Disease stage | |
| Adjuvant setting | 12 (12) |
| Palliative setting | 92 (88) |
| local tumor recurrence | 15 (14) |
| distant metastases | 77 (74) |
| Drug | |
| Nivolumab | 66 (64) |
| Pembrolizumab | 24 (23) |
| Durvalumab | 9 (9) |
| Other | 5 (5) |
| Concomitant chemotherapy | 6 (6) |
| Comorbidityb (n = 199) | |
| Arterial hypertonia | 34 (33) |
| Cardiovascular comorbidity | 30 (29) |
| Diabetes | 20 (19) |
| COPD | 18 (17) |
| Autoimmune disease | 2 (2) |
| Other | 87 (84) |
| None | 8 (8) |